The GLP-1 telehealth space is overcrowded, and most of it looks identical. Same stock photos, same vague promises, same invoice surprises. A handful of providers actually stand apart, and the differences matter more than marketing suggests.
Here is how to think through your options, with the six that come up most often in real conversations about what works.
1. HealthRX
Start here if price is your constraint and overnight access matters.
HealthRX writes compounded semaglutide from $99 per month and compounded tirzepatide from $149 per month, which genuinely undercuts most of this list at the entry level. Free overnight shipping goes to all 50 states. No contracts, no hidden fees, pricing is posted plainly. A US board-certified physician reviews your intake within roughly 24 hours, and medication ships the same day approval comes through.
The pharmacy question is one most patients never think to ask. They should. HealthRX dispenses through Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy operating under USP-797 standards with lot-tracked batches from bench to door. LegitScript certification (number 50087439) is publicly verifiable. That level of supply-chain specificity is not standard across the telehealth field.
The trial data HealthRX references is trial-based, not its own outcomes: tirzepatide showed roughly 21 percent body weight reduction at 72 weeks in SURMOUNT-1; semaglutide showed roughly 15 percent at 68 weeks in STEP 1. Compounded versions are not FDA-approved, and no telehealth provider can guarantee those numbers for any individual patient.
For the right patient, this is a strong opening option.
2. FormBlends
FormBlends lands at number two for a specific reason: it publishes batch-level purity data.
Most GLP-1 telehealth brands tell you their compounding pharmacy is “reputable.” FormBlends names the numbers. HPLC purity, mass spectrometry identity confirmation, endotoxin and sterility results are published per product. For patients who have read about the FDA warning letters issued to 30-plus telehealth and compounding operations in early 2026, that kind of documentation is not a minor detail.
Pricing runs higher than HealthRX. Compounded semaglutide is around $299 per vial and tirzepatide around $349, with transparent per-vial cash pricing. The provider operates with physician oversight and dispenses through an FDA-registered 503A compounding pharmacy. Shipping covers 47 states, not all 50.
FormBlends also carries a broader catalog than any pure GLP-1 shop, including peptides used for recovery, longevity, and cognition, all under the same clinical model. If you want GLP-1 treatment now and want to expand into other peptide protocols later without switching providers, that matters. If you just want the lowest monthly cost, HealthRX is the better fit.
3. Mochi Health
Mochi has built a reputation for putting actual obesity-medicine-trained clinicians on cases, not just general practitioners signing off. That shows up in the monitoring depth. Compounded semaglutide runs around $99 per month and compounded tirzepatide around $199 per month, which is competitive. The trade-off is a more involved onboarding and check-in process. Some patients want that. Others find it slower than they expected.
4. Ro Body
Ro has the infrastructure of a scaled telehealth company. Its prior-authorization team actively works insurance coverage for branded GLP-1 medications, which is a real operational effort most smaller providers skip entirely. The first month runs around $39 for membership, then $74 to $149 monthly. Medications are billed separately. For patients who have commercial insurance with GLP-1 coverage and want someone to fight the approval process with them, Ro is one of the more organized options in this category.
5. Hims and Hers
Hims and Hers exited compounded GLP-1 products after the Novo Nordisk settlement in March 2026 and shifted to branded medications. Injectable Wegovy is priced around $299 per month through the platform; oral options run around $249; Zepbound sits around $399. With insurance and a manufacturer savings card, out-of-pocket costs can drop to the $0 to $25 range for eligible patients. The brand recognition and app experience are polished. This is a reasonable option if you want branded meds and have coverage, but cash-pay costs without insurance are substantially higher than several alternatives above.
6. PlushCare
PlushCare is worth mentioning for a different reason than the others. It functions as a general telehealth platform first, weight management second. Membership is about $19.99 per month. Same-day visits are available in many cases. It accepts insurance, bills branded medications through standard prescription channels, and handles a wide range of primary care needs beyond GLP-1s. Patients who want their weight management integrated into broader primary care rather than siloed in a specialty app may find it a more sensible fit.
How to Actually Choose
Price is only part of it. Figure out whether you want compounded or branded medication. If compounded, ask specifically where it is dispensed and what quality controls apply. If you have insurance with any GLP-1 benefit, a provider with real prior-auth support changes the math entirely. Monitoring depth varies widely across this list, and some patients genuinely need more clinical oversight than others.
Common Questions
Does it actually matter which compounding pharmacy a virtual clinic uses?
Yes, and it matters more than most patients realize. 503A pharmacies operate under state board oversight, and quality controls vary significantly between facilities. Asking for the pharmacy name, its USP-797 compliance status, and whether batch-level testing results are published will tell you more about safety than any clinic’s marketing language.
If Hims and Hers stopped offering compounded GLP-1s, which providers on this list still offer them?
As of Q1-Q2 2026, HealthRX, FormBlends, Mochi Health, and Ro Body all still offered compounded semaglutide or tirzepatide. Hims and Hers shifted to branded medications only following the Novo Nordisk settlement in March 2026. PlushCare focuses on branded prescriptions billed through standard pharmacy channels.
Is Mochi Health’s more involved onboarding process worth the extra time compared to faster options like HealthRX?
It depends on your health history. Patients with multiple comorbidities, prior medication reactions, or complex metabolic situations tend to benefit from Mochi’s obesity-medicine-trained clinicians and deeper check-in cadence. If you are otherwise healthy and want fast approval and low cost, HealthRX’s 24-hour physician review is a reasonable alternative.
What does FormBlends’ batch-level purity documentation actually include, and why does it matter?
FormBlends publishes HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility test results per product batch. This matters because the FDA issued warning letters to more than 30 compounding and telehealth operations in early 2026, often for potency or contamination failures that patients had no way to detect without exactly this kind of third-party testing data.
Can PlushCare handle both my GLP-1 prescription and other ongoing health issues, or is it better to use a dedicated weight loss clinic?
PlushCare can handle both. It operates as a general telehealth platform with primary care capabilities, so it accepts insurance and manages conditions beyond weight loss in the same membership. The trade-off is that it does not specialize in GLP-1 protocols the way Mochi or HealthRX do, so patients specifically optimizing a tirzepatide or semaglutide titration schedule may want a more focused provider.
A Note Before You Proceed
Compounded GLP-1 medications are not FDA-approved, even when produced by a legitimate 503A pharmacy. Individual results vary widely from clinical trial averages. Talk to a physician about your full health picture before starting any weight loss medication. This article does not constitute medical advice.
Sources
- FDA, warning letters to telehealth and compounding firms (2026), FDA.gov
- SURMOUNT-1 trial, tirzepatide weight loss data, published in *New England Journal of Medicine* (2022)
- STEP 1 trial, semaglutide weight loss data, published in *New England Journal of Medicine* (2021)
- LegitScript certification database, LegitScript.com
- Novo Nordisk settlement announcement, March 2026, public press coverage
- Individual platform pricing pages, verified Q1-Q2 2026
